Juan Antonio García-Carmona, Alba García-Pérez, Guillermo Isidro García, Luis Alberto Forcen-Muñoz, Santiago Ovejero García, Rocío Sáez Povedano, Ana Luisa González-Galdámez, Laura Mata Iturralde, Fernando Hernández-Sánchez, Mariluz Ramirez Bonilla, Paloma Fuentes-Pérez, Claudia Ovejas-Catalán, Paula Suárez-Pinilla, Francisco Valdivia-Muñoz, Blanca Fernández Abascal, Miguel Omaña Colmenares, Ángela de Lourdes Martín-Pérez, María Pilar Campos-Navarro, Enrique Baca-García, Sergio Benavente-López, Alberto Raya Platero, Miguel Barberán Navalón, Sergio Sánchez-Alonso, Javier Vázquez-Bourgon, Sofia Pappa
BACKGROUND: Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there is presently limited insight into its effectiveness and potential added value in real clinical practice conditions. OBJECTIVES: To present our ongoing study and draw its preliminary data on patient characteristics initiating PP6M and adherence during the first year of treatment. METHODS: The paliperidone 2 per year (P2Y) study is a 4-year, multicentre, prospective mirror-image pragmatic study taking place at over 20 different sites in Europe...
2023: Therapeutic Advances in Psychopharmacology